Aclaris Therapts (ACRS) Stock Price, Quote & News

Company Profile

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2...

Industry: Biotechnology

Sector: Healthcare

Phone: 484 324 7933

Website: www.aclaristx.com

Address:

701 Lee Road, Suite 103, Wayne, United States

Acan1219 Mar. 14 at 11:37 PM

$ACRS Yes it is! Something Big is on the Horizon!

0 · Reply

buymoremakemore Mar. 13 at 10:27 PM

$ACRS We should have cash into the 2nd half of 2029 now. Thats huge.

0 · Reply

savemefrom925 Mar. 12 at 8:41 PM

$ACRS please tell me the 12% drop is a glitch

1 · Reply

OriginalTradeonrumor Mar. 12 at 8:30 PM

$ACRS the performance of this stock is very bullish …buying in 3.40’s /30’s is a gift

0 · Reply

dibatista Mar. 12 at 6:55 PM

$ACRS AGAIN!!

0 · Reply

Acan1219 Mar. 12 at 6:46 PM

$ACRS we’re going Green My Bull’s!

0 · Reply

Acan1219 Mar. 11 at 9:28 PM

$ACRS Here’s the other Investors who just bought over 5 Million SH’s! We are ready for a Double Digit Move!

1 · Reply

Bionco Mar. 11 at 8:59 PM

$ACRS Another 5.7 million shares sold yesterday. Those moves may have raised enough capital to fund the company's operations for an additional year.

0 · Reply

Puffyk Mar. 11 at 8:41 PM

$ACRS the road to $12 continues

0 · Reply

dibatista Mar. 11 at 7:53 PM

$ACRS great recovery

0 · Reply

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Feb 24, 2026, 7:00 AM EST - 19 days ago

Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Patients with Asthma with its Novel Bispecific Anti-TSLP/IL-4Rα Antibody ATI-052

Jan 27, 2026, 6:55 AM EST - 6 weeks ago

Aclaris Therapeutics' Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA)

Jan 12, 2026, 6:55 AM EST - 2 months ago

Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Atopic Dermatitis (AD) with Its Novel Bispecific Antibody ATI-052

Jan 6, 2026, 3:58 PM EST - 2 months ago

Aclaris Therapeutics, Inc. (ACRS) Discusses Positive Interim Results From ATI-052 Phase 1a Trial and Potential Therapeutic Advantages Transcript

Jan 6, 2026, 6:59 AM EST - 2 months ago

Aclaris Therapeutics Announces Positive Interim Results of Phase 1a Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Supporting Expedited Clinical Development

Dec 19, 2025, 4:01 PM EST - 3 months ago

Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI)

Nov 25, 2025, 8:00 AM EST - 3 months ago

Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

Nov 6, 2025, 6:59 AM EST - 4 months ago

Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 29, 2025, 7:30 AM EDT - 4 months ago

Aclaris Therapeutics to Participate in Three November Healthcare Conferences

Oct 14, 2025, 5:46 PM EDT - 5 months ago

Aclaris Therapeutics, Inc. - Special Call

Sep 30, 2025, 7:00 AM EDT - 5 months ago

Aclaris Therapeutics to Host In-Person and Webcast R&D Day, “Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets”, in New York on October 14, 2025

Sep 9, 2025, 7:00 AM EDT - 6 months ago

Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology (EADV) Congress

Aug 27, 2025, 8:00 AM EDT - 7 months ago

Aclaris Therapeutics to Participate in Two September Healthcare Conferences

Aug 7, 2025, 6:59 AM EDT - 7 months ago

Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jul 29, 2025, 4:01 PM EDT - 8 months ago

Aclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3; Trial Achieves Primary and Key Secondary Endpoints

Jul 28, 2025, 8:45 AM EDT - 8 months ago

Aclaris Therapeutics Announces Leadership Transition

Jun 30, 2025, 9:31 AM EDT - 9 months ago

Aclaris Therapeutics Added to the Russell 2000® and Russell 3000® Indexes

Jun 26, 2025, 4:01 PM EDT - 9 months ago

Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference

Jun 23, 2025, 6:59 AM EDT - 9 months ago

Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052

May 28, 2025, 9:20 AM EDT - 10 months ago

Aclaris Therapeutics to Participate in Two June Healthcare Conferences

May 9, 2025, 7:00 AM EDT - 11 months ago

Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series

May 8, 2025, 6:50 AM EDT - 11 months ago

Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Apr 29, 2025, 7:00 AM EDT - 11 months ago

Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer

Mar 4, 2025, 7:00 AM EST - 1 year ago

Aclaris Therapeutics to Participate in Two March Healthcare Conferences

Feb 12, 2025, 6:50 AM EST - 1 year ago

New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3

Jan 30, 2025, 4:01 PM EST - 1 year ago

Aclaris Therapeutics Announces Formation of New Scientific Advisory Board

Jan 6, 2025, 4:30 PM EST - 1 year ago

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Dec 23, 2024, 1:41 PM EST - 1 year ago

Aclaris Stock Rises As Analyst Projects Billions In Sales For New Therapy

Nov 26, 2024, 4:30 PM EST - 1 year ago

Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 19, 2024, 3:27 PM EST - 1 year ago

Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments

Nov 18, 2024, 8:50 AM EST - 1 year ago

Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets

Nov 18, 2024, 8:10 AM EST - 1 year ago

Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline

Nov 18, 2024, 8:10 AM EST - 1 year ago

Aclaris Therapeutics Announces $80 Million Private Placement

Sep 17, 2024, 7:00 AM EDT - 1 year ago

Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis

Sep 10, 2024, 7:00 AM EDT - 1 year ago

Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference

Jul 16, 2024, 4:01 PM EDT - 1 year ago

Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million

Jun 25, 2024, 12:36 PM EDT - 1 year ago

Rheumatoid Arthritis Market and Epidemiology Forecast 2024-2034 Featuring Analysis of ATI-450 (Aclaris Therapeutics) and Olumiant/Baricitinib (Eli Lilly/Incyte)

Jun 6, 2024, 7:00 AM EDT - 1 year ago

Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

May 8, 2024, 6:30 AM EDT - 2 years ago

American Clinical Research Services Announces Strategic Acquisition of Elixia

May 7, 2024, 9:44 PM EDT - 2 years ago

Aclaris Therapeutics, Inc. (ACRS) Q1 2024 Earnings Call Transcript

May 7, 2024, 4:01 PM EDT - 2 years ago

Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

Apr 23, 2024, 8:00 AM EDT - 2 years ago

Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer

Feb 27, 2024, 7:00 AM EST - 2 years ago

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update

Jan 10, 2024, 7:00 AM EST - 2 years ago

Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis

Dec 19, 2023, 4:01 PM EST - 2 years ago

Aclaris Therapeutics Provides Corporate Update

Dec 5, 2023, 4:01 PM EST - 2 years ago

Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for Alopecia

Nov 13, 2023, 7:19 AM EST - 2 years ago

Aclaris Therapeutics to stop development of rheumatoid arthritis drug

Nov 13, 2023, 7:00 AM EST - 2 years ago

Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate Update

Nov 6, 2023, 7:00 AM EST - 2 years ago

Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate Update

Acan1219 Mar. 14 at 11:37 PM

$ACRS Yes it is! Something Big is on the Horizon!

0 · Reply

buymoremakemore Mar. 13 at 10:27 PM

$ACRS We should have cash into the 2nd half of 2029 now. Thats huge.

0 · Reply

savemefrom925 Mar. 12 at 8:41 PM

$ACRS please tell me the 12% drop is a glitch

1 · Reply

OriginalTradeonrumor Mar. 12 at 8:30 PM

$ACRS the performance of this stock is very bullish …buying in 3.40’s /30’s is a gift

0 · Reply

dibatista Mar. 12 at 6:55 PM

$ACRS AGAIN!!

0 · Reply

Acan1219 Mar. 12 at 6:46 PM

$ACRS we’re going Green My Bull’s!

0 · Reply

Acan1219 Mar. 11 at 9:28 PM

$ACRS Here’s the other Investors who just bought over 5 Million SH’s! We are ready for a Double Digit Move!

1 · Reply

Bionco Mar. 11 at 8:59 PM

$ACRS Another 5.7 million shares sold yesterday. Those moves may have raised enough capital to fund the company's operations for an additional year.

0 · Reply

Puffyk Mar. 11 at 8:41 PM

$ACRS the road to $12 continues

0 · Reply

dibatista Mar. 11 at 7:53 PM

$ACRS great recovery

0 · Reply

Acan1219 Mar. 11 at 7:50 PM

$ACRS Charging Back like a Bull to the Green!!

0 · Reply

Acan1219 Mar. 11 at 3:57 PM

$ACRS Let’s Gooo my Bull’s!

0 · Reply

Acan1219 Mar. 11 at 3:46 PM

$ACRS The 12.7 Million SH’s bought by Deep Track Investment’s are Definitely in the Right Hands!! Double Digits Coming!

1 · Reply

Bionco Mar. 11 at 3:16 PM

$ACRS In the past three weeks, we’ve learned a lot about how market makers manipulate stocks.😁

0 · Reply

buymoremakemore Mar. 10 at 6:55 PM

$ACRS Looks like Deep Track has history as an activist investor. Deep Track holds several bio companies recently bought out like 89 bio and akero. So if they keep buying shares maybe ittl be a sign. I dont see why this doesnt get bought out. So many shots at goal not even including next gen ITK https://www.fiercebiotech.com/biotech/dynavaxs-feud-activist-investor-heats-ahead-annual-meeting

1 · Reply

buymoremakemore Mar. 10 at 5:27 PM

$ACRS bought another 2500 shares so that I could make more. 10,000 shares. Already made $100,000 here. Will play it safe with smaller position with a baby on the way. Optimistic this goes to $20.

0 · Reply

buymoremakemore Mar. 10 at 5:24 PM

$ACRS tempted to buy more!

0 · Reply

Puffyk Mar. 10 at 4:27 PM

$ACRS setting up for the run to $12. They just made $39 Million purchased by investment firm. Announcement of what is about to happen gets us to $12. Any additional short squeeze could push yo to $18 REAL FAST

1 · Reply

Bionco Mar. 10 at 3:28 PM

$ACRS Wow! They just tapped into the ATM facility again!

1 · Reply

OriginalTradeonrumor Mar. 10 at 2:31 PM

$ACRS hoping some of you followed my advice at going all in in the 2.80’s——I sold 80% of my holdings in 3.50’s..last chunk had limit at 3.57 ( thank you MM’s!). Hold small position 20k to see if we hit 3.75 where I’ll sell 10k at around there and hold rest to see if we retest 4.50…other that that I stop at 3.25 and wait for next trip

0 · Reply

Bionco Mar. 10 at 10:17 AM

$ACRS The company sold 12.7 million shares over the past seven days, possibly including yesterday’s transaction of 9.44 million shares and a subsequent block of 110K shares. The question is: who bought them?

2 · Reply

RunnerSignals Mar. 9 at 9:01 PM

Market Warriors $AAOI $CCCC $AEHR $EDIT $ACRS red at the open, green by the close dip buyers stepped in hard and the tape turned fast

0 · Reply

Market Cap	426.91M
Revenue (ttm)	7.83M
Net Income (ttm)	-64.92M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-829.12%
Debt to Equity Ratio	0.00

Volume	899,600
Avg Vol	2,486,816
Day's Range	N/A - N/A
Shares Out	120.60M
Stochastic %K	76%
Beta	0.88
Analysts	Strong Sell
Price Target	$8.29